Key result
Pantoprazole offers advantages in the treatment and prevention of aspirin-induced gastropathy in patients with ischemic heart disease due to its low risk of drug interactions and good clinical efficacy.
Pantoprazole and cytoprotectors are recommended for the treatment and prevention of aspirin-induced gastropathy in patients with ischemic heart disease due to low interaction risks.
Answers are grounded in this paper and cite their sources.
May warrant GI monitoring in CVD patients on low-dose ASA; hypothesis-generating for H. pylori eradication in gastropathy prevention.
The erosive ulcerous affections of gastrointestinal tract in patients with cardiovascular diseases occur frequently and are conditioned by both ischemia of organs of digestion against the background of reduced cardiac output and intake of low doses of acetylsalicylic acid combined with anti-coagulants. The bleeding can be the first and the only manifestation of gastroduodenal pathology. The treatment and prevention of aspirin-induced gastropathy provides for implementation of eradication of Helicobacter pylori infection, application of cyto-protectors (Misoprostol or Bismuthate tripotassium dicitrate), long-term using of inhibitors of proton pump. Out of them Pantoprazole has a certain advantage at the expense low risk of medicinal interactions, good clinical efficiency and anti-inflammatory effect.
No takes yet. Share an insight, caveat, or question.
Лузина et al. (2017) conducted a review in Ischemic heart disease and aspirin-induced gastropathy. Proton pump inhibitors (especially Pantoprazole) was evaluated. Pantoprazole offers advantages in the treatment and prevention of aspirin-induced gastropathy in patients with ischemic heart disease due to its low risk of drug interactions and good clinical efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: